Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

NCT01021956 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Retinal vascular occlusion in 2 patients

Conditions

Macular Degeneration
Choroidal Neovascularization

Interventions

DRUG: STAKEL

Sponsor

Steba Biotech S.A.